Myxovirus resistance protein A (MxA) is a molecule induced after interferon-beta injection, mostly used to evaluate its bioactivity. There is little available data on clinical utility of baseline MxA mRNA status. The objective of the study is to investigate whether baseline MxA mRNA expression can predict relapse and disease progression in multiple sclerosis patients treated with interferon-beta. Baseline blood samples were obtained before the first interferon-beta dose was administered to evaluate MxA mRNA expression using real-time polymerase chain reaction (PCR). Demographic and clinical variables were prospectively recorded to define treatment responder and non responder groups. 104 patients were included in the study. Baseline MxA mRNA expression was significantly lower in the group of patients who met the definition of responders (1.07 vs 1.95, Student t test, p<0.0001). A threshold of 1.096 was established using Receiver Operating Characteristic analysis to differentiate between responders and non-responders (sensitivity 73.9%, specificity 69.0%). Survival analysis using this threshold showed that time to next relapse (p<0.0001) and to EDSS progression (p = 0.01) were significantly higher in patients with lower MxA titers. The results suggest that baseline MxA mRNA levels may be useful for predicting whether multiple sclerosis patients will respond or not to interferon-beta treatment.
29 July 2025 in Multiple Sclerosis and Related Disorders
The 2024 revision of the McDonald criteria introduces specific recommendations for diagnosing late-onset multiple sclerosis (LOMS). One of the following criteria must be met: spinal cord lesions, positive cerebrospinal fluid (CSF) findings, or fulfilment of the Select-6 criteria (i.e., six or more central vein signs on brain magnetic resonance imaging (MRI)). To evaluate the sensitivity of the 2024 McDonald criteria in patients with LOMS and to identify the most sensitive diagnostic test. This cross-sectional, observational, retrospective study included patients diagnosed with LOMS (onset ≥50 years of age) who were followed at the Multiple Sclerosis Clinic of Bellvitge University Hospital. Clinical records, MRI scans, and CSF analyses were reviewed to assess the presence of spinal cord lesions, central vein signs and oligoclonal bands (OCBs). The sensitivity of the 2024 recommended LOMS criteria was analysed. 115 patients met at least one of the proposed 2024 LOMS diagnostic criteria, resulting in a sensitivity of 100 %. Of these, 10.4 % fulfilled all three criteria, 52.1 % met two criteria (most commonly OCBs and spinal lesions). The remaining 37.4 % met only one: 53.5 % had spinal lesions, 46.5 % were positive for OCBs, and none met only the Select-6 criterion. The difference between the proportions meeting the OCB and spinal cord lesion criteria was not statistically significant (p = 0.581), but both were significantly more common than meeting the Select-6 criterion (p < 0.001). The 2024 McDonald criteria maintain high sensitivity for diagnosing LOMS. CSF analysis and spinal MRI are the most valuable tools, whereas the Select-6 criteria exhibited a lower diagnostic value.
Background: People with multiple sclerosis (MS) present varying degrees of disability throughout their disease course. The Multiple Sclerosis Severity Score (MSSS) and the Age-Related Multiple Sclerosis Severity Score (ARMSSS) adjust the Expanded Disability Status Scale (EDSS) according to disease duration and age, respectively. These measures could be useful for quantifying MS severity and as health outcome indicators for benchmarking in population-based settings. The aim of this study was to describe the severity of MS in our health district using the MSSS and ARMSSS and to assess their consistency over time. Methods: This population-based study included patients from our health district who were diagnosed with MS according to the 2010 McDonald criteria, had a disease duration of at least one year and were followed up in our MS unit. Sex, age at onset, disease duration, clinical course, age and irreversible EDSS at the last follow-up visit were collected, and the MSSS and ARMSSS were calculated at two time points: 2017 and 2020. Results: One hundred seventy-seven patients were included in 2017, and 208 in 2020. The prevalence of MS was 90 and 104 per 100,000 inhabitants, respectively. The median MSSS was 1.77 (IQR 0.76–4.28) in 2017 and 2.03 (IQR 0.82–4.36) in 2020. The median ARMSSS was 2.90 (IQR 1.47–5.72) in 2017 and 2.93 (IQR 1.51–5.56) in 2020. No significant differences were found. Conclusions: According to the MSSS and ARMSSS, the severity of MS in our area is mild, and these instruments are consistent. These measures could be reliable health outcome measures.